Julita Borkowska

Julita Borkowska

Auto-generated profile, based on publicly available information

Julita Borkowska

Department of Neurology and Epileptology, The Children's Memorial Health Institute, Warsaw, Poland

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2011 in European Journal of Paediatric Neurology
Verified
Journal Article
Open access
Sergiusz JóźwiakSergiusz Jóźwiak
Sergiusz Jóźwiak
KKKatarzyna Kotulska-Jóźwiak
Katarzyna Kotulska-Jóźwiak
DDDorota Domańska-Pakieła
Dorota Domańska-Pakieła
BŁBarbara Łojszczyk
Barbara Łojszczyk
MSMalgorzata Syczewska
Malgorzata Syczewska
MRMaria Respondek-Liberska
Maria Respondek-Liberska
Epilepsy appears in 70-80% of patients with tuberous sclerosis complex, most commonly in the first year of age. Early manifestation of epilepsy is associated with drug-resistant epilepsy and mental retardation in more than 80% of patients. Clinical epileptic seizures are preceded by deterioration of EEG recording thus infants with high risk of epilepsy can be identified. We hypothesized that preventative antiepileptic treatment of infants with multifocal activity on EEG might lower the incidence of drug-resistant epilepsy and mental retardation. Forty-five infants with early diagnosis of tuberous sclerosis complex were included in the open-label study. They were divided in two groups: standard (n=31) and preventative one (n=14). In standard group the antiepileptic treatment was launched early, but after the onset of seizures. In preventative group medication was commenced when active epileptic discharges were seen on EEG, but before the onset of clinical seizures. Children were followed till the end of 2 years of age. At 24 months of age mental retardation was significantly more frequent and severe in "standard" vs "preventative" group (48% vs 14%; p=0.031; mean IQ score 68.7 vs 92.3; p<0.05). The "preventative" group was characterized by higher ratio of seizure-free patients (93% vs 35%; p=0.004), lower incidence of drug-resistant epilepsy (7% vs 42%; p=0.021) and lower number of patients requiring polytherapy (21% vs 55%; 0.039) than the "standard group. Preventative antiepileptic treatment of infants with tuberous sclerosis complex and high risk of epilepsy markedly improves their neurodevelopmental outcome and reduces the incidence of drug-resistant seizures.

23 December 2010 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
JBJulita Borkowska
Julita Borkowska
Robert A SchwartzRobert A Schwartz
Robert A Schwartz
KKKatarzyna Kotulska-Jóźwiak
Katarzyna Kotulska-Jóźwiak
Sergiusz JóźwiakSergiusz Jóźwiak
Sergiusz Jóźwiak

29 January 2018 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
MSMonika Słowińska
Monika Słowińska
Sergiusz JóźwiakSergiusz Jóźwiak
Sergiusz Jóźwiak
Angela PeronAngela Peron
Angela Peron
JBJulita Borkowska
Julita Borkowska
DCDariusz Chmielewski
Dariusz Chmielewski
KKKatarzyna Kotulska-Jóźwiak
Katarzyna Kotulska-Jóźwiak
Tuberous sclerosis complex (TSC) is a genetic disorder with an incidence of 1:6000 live births and associated with the development of benign tumors in several organs. It is also characterized by high rates of neurological and neuropsychiatric abnormalities, including epilepsy affecting 70–90% of patients and being one of the major risk factors of intellectual disability. The first seizures in TSC patients appear usually between the 4th and the 6th months of life. Recent studies have shown the beneficial role of preventative antiepileptic treatment in TSC patients, with the possibility for improvement of cognitive outcome. Moreover, European recommendations suggest early introduction of Vigabatrin if ictal discharges occur on EEG recordings, with or without clinical manifestation. The aim of this study was to define the most useful approach to make the diagnosis of TSC before seizure onset (before age 4th months), in order to start early EEG monitoring with possible preventative treatment intervention. We performed a retrospective review of children who were suspected of having TSC due to single or multiple cardiac tumors as the first sign of the disease. We analyzed the medical records in terms of conducted clinical tests and TSC signs, which were observed until the end of the 4th month of age. Subsequently, we described the different clinical scenarios and recommendations for early diagnosis. 82/100 children were diagnosed with TSC within the first 4 months of life. Apart from cardiac tumors, the most frequently observed early TSC signs were subependymal nodules (71/100, 71%), cortical dysplasia (66/100, 66%), and hypomelanotic macules (35/100, 35%). The most useful clinical studies for early TSC diagnosis were brain magnetic resonance imaging (MRI), skin examination and echocardiography. Genetic testing was performed in 49/100 of the patients, but the results were obtained within the first 4 months of life in only 3 children. Early diagnosis of TSC, before seizure onset, is feasible and it is becoming pivotal for epilepsy management and improvement of cognitive outcome. Early TSC diagnosis is mostly based on clinical signs. Brain MRI, echocardiography, skin examination and genetic testing should be performed early in every patient suspected of having TSC.

1 September 2013 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
KKKatarzyna Kotulska-Jóźwiak
Katarzyna Kotulska-Jóźwiak
DCDariusz Chmielewski
Dariusz Chmielewski
JBJulita Borkowska
Julita Borkowska
EJElzbieta Jurkiewicz
Elzbieta Jurkiewicz
DKDariusz Kuczyński
Dariusz Kuczyński
Sergiusz JóźwiakSergiusz Jóźwiak
Sergiusz Jóźwiak

1 April 2014 in Pediatric Neurology
Verified
Journal Article
Closed access
KKKatarzyna Kotulska-Jóźwiak
Katarzyna Kotulska-Jóźwiak
JBJulita Borkowska
Julita Borkowska
MRMarcin Roszkowski
Marcin Roszkowski
Marek ManderaMarek Mandera
Marek Mandera
PDPaweł Daszkiewicz
Paweł Daszkiewicz
Sergiusz JóźwiakSergiusz Jóźwiak
Sergiusz Jóźwiak

17 September 2014 in Child's Nervous System
Verified
Journal Article
Open access
PDF file
KKKatarzyna Kotulska-Jóźwiak
Katarzyna Kotulska-Jóźwiak
JBJulita Borkowska
Julita Borkowska
Marek ManderaMarek Mandera
Marek Mandera
MRMarcin Roszkowski
Marcin Roszkowski
EJElzbieta Jurkiewicz
Elzbieta Jurkiewicz
Sergiusz JóźwiakSergiusz Jóźwiak
Sergiusz Jóźwiak
Purpose Subependymal giant cell astrocytoma (SEGA) is a brain tumor associated with tuberous sclerosis complex (TSC). It usually grows in a second decade of life, but may develop in the first months of life. The aim of this work was to establish the incidence, clinical features, and outcome of congenital SEGA in TSC patients. Methods Cohort of 452 TSC patients was reviewed to identify cases with growing or hydrocephalus producing SEGAs in the first 3 months of life. Clinical presentation, size of the tumor, growth rate, mutational analysis, treatment applied, and outcome were analyzed. Results Ten (2.2 %) patients presented with SEGA in the first 3 months of life. All of them had documented SEGA growth and all developed hydrocephalus. In eight patients, mutational analysis was done, and in all of them, TSC2 gene mutations were identified. Mean maximum SEGA diameter at baseline was 21.8 mm. Mean SEGA growth rate observed postnatally was 2.78 mm per month and tended to be higher (5.43 mm per month) in patients with TSC2/PKD1 mutation than in other cases. Seven patients underwent SEGA surgery and surgery-related complications were observed in 57.1 % cases. One patient was successfully treated with everolimus as a primary treatment. Conclusions Congenital SEGA develops 2.2 % of TSC patients. Patients with TSC2 mutations, and especially with TSC2/PKD1 mutations, are more prone to develop SEGA earlier in childhood and should be screened for SEGA from birth. In young infants with SEGA, both surgery and mTOR inhibitor should be considered as a treatment option.